Searchable abstracts of presentations at key conferences in endocrinology

ea0032p512 | Endocrine tumours and neoplasia | ECE2013

Biochemical diagnosis of pheochromocytoma using plasma free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions

Darr Roland , Peitzsch Mirko , Pamporaki Christina , Prejbisz Aleksander , Fassnacht Martin , Beuschlein Felix , Neumann Hartmut , Januszewicz Andrzej , Lenders Jacques , Eisenhofer Graeme

Objective: To document influences of sampling of blood under supine fasting versus seated non-fasting conditions on diagnosis of pheochromocytoma using plasma concentrations of normetanephrine, metanephrine and methoxytyramine (P-NMN/MN/MTY).Design and methods: P-NMN/MN/MTY were measured by liquid chromatography with tandem mass spectrometry in 695 patients at five centers, two of which complied with requirements for supine sampling after an overnight fa...

ea0032p516 | Endocrine tumours and neoplasia | ECE2013

Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma

Kerkhofs Thomas , Baudin Eric , Terzolo Massimo , Allolio Bruno , Chadarevian Rita , Leboulleux Sophie , Mantero Franco , Haak Harm , Fassnacht Martin

Introduction: Current medical treatment of adrenocortical carcinoma (ACC) is based on mitotane alone or in combination with cytotoxic chemotherapy. However, very little is known about the pharmacokinetic properties of mitotane and dosing schedules are based on clinical experience only. The aim of this study was to investigate the relationship between mitotane dose and plasma concentration comparing two pre-defined treatment regimens. Secondary objectives were to evaluate safet...

ea0026oc2.1 | Neuroendocrinology | ECE2011

Etoposide, doxorubicin, cisplatin, and mitotane versus streptozotocin and mitotane in adrenocortical carcinoma: preliminary results from the first international phase III trial: the FIRM-ACT study

Fassnacht Martin , Terzolo Massimo , Allolio Bruno , Baudin Eric , Haak Harm , Berruti Alfredo , Mueller Hans-Helge , Skogseid Britt

Background: No randomized trials have been conducted in adrenocortical carcinoma (ACC) patients. Treatment recommendations for this rare but aggressive disease have been based on data from small phase II trials. We have now performed the first randomized phase III trial, comparing etoposide, doxorubicin, cisplatin, plus mitotane (EDP-M) against streptozotocin plus mitotane (Sz-M).Methods: Three-hundred and four chemotherapy-naive patients with ACC not am...

ea0026p232 | Pituitary | ECE2011

Copeptin in the differential diagnosis of the polydipsia–polyuria syndrome: revisiting the direct and indirect water deprivation tests

Fenske W K , Quinkler M , Haagen U , Papassotiriou J , Pfeiffer A F H , Fassnacht M , Stoerk S , Allolio B

Background: The water deprivation test (WDT) with direct or indirect measurement of plasma vasopressin (AVP) is the method of choice for the differential diagnosis of the polydipsia–polyuria syndrome. In theory, direct measurement of AVP is highly attractive but hampered by technical difficulties.Objective: To evaluate the utility of copeptin, a surrogate of AVP secretion, in the diagnostic work-up of the polyuria–polydipsia syndrome, and to co...

ea0022p711 | Obesity | ECE2010

Limited weight loss with gastric banding in patients with craniopharyngeoma

Weismann Dirk , Pelka Theresia , Bender Gwendolyn , Muller Herrmann , Gebhardt Ursel , Thalheimer Andreas , Jurowich Christian , Fassnacht Martin , Allolio Bruno

While bariatric surgery is the most effective treatment strategy to maintain long-term weight-loss and to improve survival, it has not been shown, that bariatric surgery is as effective in craniopharyngeoma patients with hypothalamic obesity. We retrospectively analyzed weight loss and metabolic parameters in 7 craniopharyngeoma patients and 14 controls who underwent gastric banding surgery in five centers in Germany and Austria. The last before and the first patient after the...

ea0020oc1.2 | Endocrine Tumours | ECE2009

Long-term outcome of laparoscopic versus open adrenalectomy for adrenocortical carcinoma

Fassnacht Martin , Brix David , Fenske Wiebke , Langer Peter , Nies Christoph , Agha Ayman , Beuschlein Felix , Johanssen Sarah , Riedmiller Hubertus , Allolio Bruno

Introduction: Surgery is the established first line treatment in adrenocortical carcinoma (ACC). For benign adrenal tumours, laparoscopic adrenalectomy (LA) has become the treatment of choice. However, the role of LA in ACC remains highly controversial. Data from the German ACC Registry were used to evaluate the technical feasibility of LA in ACC and to compare the long-term outcome after LA with the results of open adrenalectomy (OA).Methods: Out of 521...

ea0020p181 | Endocrine tumours and neoplasia | ECE2009

Steroidogenic factor 1 – a valuable diagnostic and prognostic tool in patients with adrenocortical carcinoma

Sbiera Silviu , Schmull Sebastian , Voelker Hans-Ullrich , Kraus Luitgard , Beuschlein Felix , Willenberg Holger , Hahner Stefanie , Allolio Bruno , Fassnacht Martin

Objectives: No immunohistochemical marker has yet been established to reliably differentiate adrenocortical tumors from other adrenal masses (e.g. metastases). Thus, a panel of several markers like melan A and inhibin is currently used for this purpose, but suffers from limited diagnostic accuracy. We hypothesized that expression of steroidogenic factor 1 (SF-1), a nuclear transcription factor involved in adrenal development and steroidogenesis, might hold significant diagnost...

ea0016p320 | Endocrine tumours | ECE2008

Mitotane induces a concentration-dependent impairment of platelet aggregation in patients with adrenocortical carcinoma

Hahner Stefanie , Eigenthaler Martin , Savvoukidis Theodoros , Johanssen Sarah , Wortmann Sebastian , Koschker Ann-Cathrin , Allolio Bruno , Fassnacht Martin

Standard treatment of adrenocortical carcinoma (ACC) comprises adrenolytic therapy with mitotane. Prolongation of bleeding time has previously been observed based on a series of 7 patients (Haak et al. 1991). As patients with ACC frequently undergo surgery for local recurrence or metastases, we have studied the effect of mitotane on coagulation in 44 patients with ACC before and/or during treatment with mitotane (total sample size n=62).Pla...

ea0014oc3.5 | Endocrine tumors & neoplasia | ECE2007

[123I]Iodometomidate as a radiotracer for adrenal scintigraphy – first clinical experience

Hahner Stefanie , Stuermer Andrea , Fassnacht Martin , Kreissl Michael , Reiners Christoph , Beuschlein Felix , Zink Martina , Zolle Ilse , Schirbel Andreas , Allolio Bruno

Adrenal masses are highly prevalent tumours comprising of a variety of entities. Therefore, therapeutic consequences also vary considerably. The CYP11B-specific PET-tracer [11C]metomidate has been shown to be suitable to characterize adrenal lesions. However, its availability is restricted to PET-centers with an on-site cyclotron. Also imaging is hindered by the short tracer half-life (20 min). Therefore, we have developed [123I]iodometomidate as a tracer...

ea0014p139 | (1) | ECE2007

Survivin – a promising target for immunotherapy in patients with adrenocortical carcinoma

Fassnacht Martin , Wortmann Sebastian , Sbiera Silviu , Kuehner Dorothee , Wobser Marion , Adam Patrick , Becker Juergen C. , Allolio Bruno

Objectives: Adrenocortical carcinoma (ACC) is a rare tumor with poor prognosis and limited therapeutic options. Survivin is an anti-apoptotic molecule expressed by neoplastic and tumor-specific endothelial cells of various carcinomas, but rarely or only weakly in normal differentiated tissue. In melanoma and pancreatic cancer, preliminary results of a survivin vaccination trial (www.clinicaltrials.gov) indicated that an immunological response in patients is often paralleled by...